Exelixis, Inc. (EXEL) stock
EXELNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends January 1
Financials through Q3 FY2026, quarter ended Oct 2, 2026Last filing: 10-Q on Oct 29, 2026Score 18/303% above fair value
$68.50+1.40 (+2.09%)
Close on Nov 17, 2026Market cap $16.71BP/E 20.5Yield –
Exelixis cash
Cash and short-term investments held at the end of each period.
Exelixis's cash was $892.02M at Oct 2, 2026. For fiscal 2025 it was $1.06B, down 4.7% from the year before. Over ten years it grew 20.1% a year on average. The highest annual figure on record is $1.48B in fiscal 2021.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Jan 2, 2026 | $1.06B | -4.7% |
| FY2024 | Jan 3, 2025 | $1.11B | +11.7% |
| FY2023 | Dec 29, 2023 | $995.30M | -24.0% |
| FY2022 | Dec 30, 2022 | $1.31B | -11.7% |
| FY2021 | Dec 31, 2021 | $1.48B | +22.8% |
| FY2020 | Jan 1, 2021 | $1.21B | +41.5% |
| FY2019 | Jan 3, 2020 | $853.88M | +23.0% |
| FY2018 | Dec 28, 2018 | $694.43M | +76.7% |
| FY2017 | Dec 29, 2017 | $392.92M | -7.3% |
| FY2016 | Dec 31, 2016 | $423.95M | +150.9% |
| FY2015 | Dec 31, 2015 | $169.00M | +17.1% |
| FY2014 | Dec 31, 2014 | $144.30M | -40.5% |
| FY2013 | Dec 31, 2013 | $242.45M | -41.1% |
| FY2012 | Dec 31, 2012 | $411.44M | +111.8% |
| FY2011 | Dec 31, 2011 | $194.26M | +19.4% |
| FY2010 | Dec 31, 2010 | $162.66M | +87.4% |
| FY2009 | Dec 31, 2009 | $86.80M | -65.0% |
| FY2008 | Dec 31, 2008 | $247.70M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Oct 2, 2026 | $892.02M | -9.8% |
| Q2 FY2026 | Jul 3, 2026 | $839.39M | +6.1% |
| Q1 FY2026 | Apr 3, 2026 | $777.21M | -24.6% |
| Q4 FY2025 | Jan 2, 2026 | $1.06B | -4.7% |
| Q3 FY2025 | Oct 3, 2025 | $988.54M | -16.9% |
| Q2 FY2025 | Jul 4, 2025 | $791.10M | -21.0% |
| Q1 FY2025 | Apr 4, 2025 | $1.03B | +7.1% |
| Q4 FY2024 | Jan 3, 2025 | $1.11B | +11.7% |
| Q3 FY2024 | Sep 27, 2024 | $1.19B | +7.8% |
| Q2 FY2024 | Jun 28, 2024 | $1.00B | -20.9% |
| Q1 FY2024 | Mar 29, 2024 | $963.26M | -26.7% |
| Q4 FY2023 | Dec 29, 2023 | $995.30M | -24.0% |
| Q3 FY2023 | Sep 29, 2023 | $1.10B | -28.7% |
| Q2 FY2023 | Jun 30, 2023 | $1.27B | -18.0% |
| Q1 FY2023 | Mar 31, 2023 | $1.31B | -17.0% |
| Q4 FY2022 | Dec 30, 2022 | $1.31B | -11.7% |
| Q3 FY2022 | Sep 30, 2022 | $1.55B | +8.0% |
| Q2 FY2022 | Jul 1, 2022 | $1.55B | +10.9% |
| Q1 FY2022 | Apr 1, 2022 | $1.58B | +28.3% |
| Q4 FY2021 | Dec 31, 2021 | $1.48B | +22.8% |
| Q3 FY2021 | Oct 1, 2021 | $1.43B | +20.5% |
| Q2 FY2021 | Jul 2, 2021 | $1.39B | +14.7% |
| Q1 FY2021 | Apr 2, 2021 | $1.24B | +29.2% |
| Q4 FY2020 | Jan 1, 2021 | $1.21B | +41.5% |
| Q3 FY2020 | Oct 2, 2020 | $1.19B | +56.2% |
| Q2 FY2020 | Jul 3, 2020 | $1.21B | +47.6% |
| Q1 FY2020 | Apr 3, 2020 | $956.00M | +19.4% |
| Q4 FY2019 | Jan 3, 2020 | $853.88M | +23.0% |
| Q3 FY2019 | Sep 27, 2019 | $761.67M | +20.0% |
| Q2 FY2019 | Jun 28, 2019 | $823.22M | +64.7% |
| Q1 FY2019 | Mar 29, 2019 | $800.75M | +87.6% |
| Q4 FY2018 | Dec 28, 2018 | $694.43M | +76.7% |
| Q3 FY2018 | Sep 28, 2018 | $634.62M | +72.9% |
| Q2 FY2018 | Jun 29, 2018 | $499.92M | +43.1% |
| Q1 FY2018 | Mar 30, 2018 | $426.92M | +0.6% |
| Q4 FY2017 | Dec 29, 2017 | $392.92M | -7.3% |
| Q3 FY2017 | Sep 30, 2017 | $367.10M | – |
| Q2 FY2017 | Jun 30, 2017 | $349.26M | – |
| Q1 FY2017 | Mar 31, 2017 | $424.27M | – |
| Q4 FY2016 | Dec 31, 2016 | $423.95M | – |
See a number that looks wrong?